Humanitas Mirasole SpA

This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study.

This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS).